PJT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PJT is not a good buy right now for an impatient investor. The stock is trading below a key support zone (S1 ~175.86) with bearish momentum (MACD histogram negative and worsening) and options positioning is strongly defensive (put/call ratios elevated). Even though fundamentals recently improved sharply and earnings are near-term, the current tape/sentiment argues for avoiding a fresh entry until price reclaims ~176–184 and momentum stabilizes.
Pre-market price is ~172.88, which is below S1 (175.861) and closer to S2 (170.679), signaling the stock is currently sitting in/near a support band rather than breaking upward. Momentum is bearish: MACD histogram is -1.298 and negatively expanding (downtrend pressure still increasing). RSI(6) is 32.32, which is weak and near oversold, implying a bounce is possible but not confirmed. Moving averages are converging, consistent with a transition phase, but with MACD worsening this currently favors continuation/downside chop rather than a clean reversal. Key levels: downside watch is 170.68 (S2); if that fails, risk of further drawdown increases. For upside, the first "prove it" level is reclaiming 175.86 (S1) and then 184.25 (pivot); above that, resistance is 192.64 (R1).
Intellectia Proprietary Trading Signals
Strong recent operating momentum: 2025/Q3 revenue +37.01% YoY, net income +79.86% YoY, EPS +86.08% YoY.
Near-term earnings event: Q4/FY2025 earnings scheduled for 2026-02-06 pre-market (can re-rate the stock quickly if results/guide beat).
Some Street targets sit above the current price (e.g., UBS PT $180; Keefe Bruyette PT $188), leaving room for upside if momentum turns.
Bearish near-term technicals: MACD is negative and deteriorating while price is below S1 (~175.86), implying trend pressure is still down.
Options positioning is notably defensive (high put/call ratios), indicating cautious sentiment into the near-term.
Analyst stance is mixed-to-cautious overall (Neutral/Market Perform cluster plus an Underperform at $150), limiting "easy" multiple expansion.
Earnings event risk is two-sided; with the stock already weak technically, a disappointment could push it through S2 (~170.68).
Latest reported quarter: 2025/Q3. Growth was strong across the board: revenue rose to 447.093M (+37.01% YoY), net income increased to 39.839M (+79.86% YoY), and EPS climbed to 1.47 (+86.08% YoY). This is a clear acceleration in profitability, supportive longer term, but the current price action suggests the market is not rewarding it yet (or is positioning cautiously ahead of the next earnings print).
Recent trend: price targets have inched up, but ratings remain mostly neutral with one notable bearish view. Keefe Bruyette raised PT to $188 (Market Perform) after previously lifting it to $186—incrementally more constructive but not a buy call. UBS initiated/assumed with Neutral and PT $180, acknowledging strong sector fundamentals but mixed valuation/expectations. Wolfe Research reiterated Underperform while raising PT to $150, keeping a cautious stance. Wall Street pros: improving targets and recognition of solid sector fundamentals/earnings power. Cons: lack of conviction buy ratings and at least one Underperform suggests upside may be more limited or already partly priced, especially near-term.
Positioning/flows check: Hedge funds and insiders are Neutral with no significant recent trends reported. No recent Congress trading data available; no noted politician/influential figure buys/sells in the provided dataset.
